E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Diabetic makula edema with visual impairment |
Diabetes makula ödem med synnedsättning |
|
E.1.1.1 | Medical condition in easily understood language |
Patients with diabetes mellitus and diabetic svelling of the makula and visual impairment |
Patienter med sockersjuka som har ögonbottenförändringar orsakade av sockersjukan med svullnad över gula fläcken och synnedsättning |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Eye Diseases [C11] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.0 |
E.1.2 | Level | HLGT |
E.1.2 | Classification code | 10012653 |
E.1.2 | Term | Diabetic complications |
E.1.2 | System Organ Class | 10014698 - Endocrine disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To study if intravitreal injection of Lucentis gives an improved visual function and a reduction of macularedema. And also objectively evaluate changes in the total retinal function and makular function with mfERG och ff ERG. |
Att studera om intravitreal Lucentis injektion ger förbättrad synfunktion och minskning av makulaödemet. Samt att objecktivt kartlägga förändringar i den totala näthinnefunktionen och makulafunktionen med mfERG och ffERG. |
|
E.2.2 | Secondary objectives of the trial |
To study if Lucentis (ranibizumab) given as an injection into the eye can improv vision and reduce the svelling of the macula. And also to evaluate changes in the retinalcell function and makular cellfunction by using an non-invasive method to measure the electical activity of the retina. |
Att studera om Lucentis (ranibizumab) givet in i glaskroppen kan förbättra synen och minska på svullnaden i gula fläcken. Samt att objektivt kartlägga retinacellerna function genom att mäta den elektriska aktiviteten i näthinnan. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Patients with type 1 or 2 diabetes mellitus
patients with clinical significant macular edema
patients with visual impairment <0.7 (Snellen)
Patients with no previous lasertreatment or other treatment for macular edema |
Patienter med diabetes
patienter med klinisk signifikant makula ödem
patienter med synnedsättning <0,7 ( Snellen)
Patienter som inte tidigare fått laserbehandling eller annan behandling för sitt makula ödem |
|
E.4 | Principal exclusion criteria |
1. Patients with active proliferative retinopathy
2. Duration of macular edema> two years
3. Cataract which causes impaired VA
4. HbA1c > 10 at baseline
5. B-glucos > 20 at baseline
6. Pregnant or nursing women
7. Fertile women not using effective contraception
8. Patients with active och suspected infection in our around the eye
9. Patientes with severe intraocular inflammation
10. Patients with uncontrolled intraocular pressure (IOP) <25 mmHg in spite of treatment 11. Intraocular surgery during the last 3 months befor enrollment
12. Previous treatment for retinaldisease such as trombosis or diabeticretinophaty |
1. Patienter med aktiv proliferativ retinopati
2. Duration av makulaödemet > två år
3. HbA1c > 10 % vid baslinjen
4. B-glukos > 20 mmol/l vid baslinjen
5. Gravida och ammande kvinnor
6. Kvinnor i fertil ålder som inte har adekvat kontraception
7. Patienter med aktiva eller misstänkta infektioner i eller runt ögat.
8. Patienter med aktiv svår intrakulär inflammation
9. Patienter med okontrollerat intraokulärt tryck (IOP) >25 mmHg trots behandling
10. Genomgången intraokulär kirurgi de senaste 3 månaderna
11. Tidigare behandling för näthinnesjukdom såsom trombos eller diabetesretinopati
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Effect on retinalcell and macular cellfunction of treatment with ranibizumab |
Effekt på retinala och makula cellers function vid behandling med ranibizumab |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
At baseline one and 3 months after injection with ranibizumab |
vid baslinjen efter 1 och 3 månader efter injection med ranibizumab |
|
E.5.2 | Secondary end point(s) |
to study if the changes in retinalfunction correlate to visual improvment and morphology changes on Optical Coherance Tomography (OCT) |
att studera om ändringar retinafunctionen korrelerar med synförbättring och med morfologiska förändringar mät med Optical Coherance Tomografi (OCT) |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
OCT will be done at baseline, 1 and 3 months after injection with ranibizumab. Visual acuity will be measured at every visit, 0, 1,2,3 months |
OCT kommer att mätas vid baslinjen samt 1 och 3 månader efter injection av ranibizumab. Synskärpa kommer att mätas vid varje återbesök, 0, 1, 2, 3 månader. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
End of trial is last visit of last subject |
Studien är slut när sista patienten gjort sitt sista besök |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | 3 |
E.8.9.1 | In the Member State concerned days | |